Pharma

Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.

Thursday, February 25, 2021 - 10:00am

The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.

Key Points: 
  • The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.
  • Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
  • Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities.
  • Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D.

Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications

Tuesday, February 23, 2021 - 2:20pm

Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation

Key Points: 
  • "We have recently announced that we have been in the process of bringing all of our manufacturing in-house," stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.
  • Nutra Pharma received Orphan Designation from the FDA for its drug, RPI-78M, for the treatment of pediatric Multiple Sclerosis.
  • As Nutra Pharma moves forward with these projects, they will provide further updates throughout the rest of 2021.
  • For additional information about Nutra Pharma, visit:

Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results

Tuesday, February 23, 2021 - 1:30pm

EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the market opens.

Key Points: 
  • EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the market opens.
  • A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.com .
  • Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

RAMM Pharma Selected as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health

Tuesday, February 23, 2021 - 12:30pm

TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Sald Publica or MSP) has selected RAMM as a fulfilment and distribution partner for Uruguays COVID-19 vaccination program.

Key Points: 
  • TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Sald Publica or MSP) has selected RAMM as a fulfilment and distribution partner for Uruguays COVID-19 vaccination program.
  • Under the arrangement, RAMM will be responsible for the sterilization, packaging and distribution of syringes and other medical supplies for use in the countrys COVID-19 vaccination program.
  • RAMMs state-of-the-art GMP certified pharmaceutical facility was selected for the program upon satisfaction of the stringent requirements of the Ministry of Public Health.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

Interpace Biosciences Announces Path Forward in Letter to Shareholders

Wednesday, February 17, 2021 - 2:21am

To align with the Companys new strategic vision Interpace will immediately embark on several initiatives to further strengthen its profile and enhance shareholder value.

Key Points: 
  • To align with the Companys new strategic vision Interpace will immediately embark on several initiatives to further strengthen its profile and enhance shareholder value.
  • In summary, Interpace is an emerging leader in the diagnostics space offering exceptional, specialized services along the therapeutic value chain.
  • I very much look forward to working with the bright, talented, and experienced team here at Interpace through the next phase of its growth.
  • Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries.

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Wednesday, February 10, 2021 - 2:00pm

KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.

Key Points: 
  • KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.
  • No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint.
  • Celon Pharma is an integrated biopharmaceutical company which designs, develops, manufactures and distributes pharmaceutical products.
  • It has been listed on the Warsaw Stock Exchange since 2016. www.celonpharma.com
    This press release (Press release) has been prepared by Celon Pharma S.A. (the Company).

Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience

Wednesday, February 10, 2021 - 12:00pm

Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions.

Key Points: 
  • Whitefish, Montana--(Newsfile Corp. - February 10, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Silo Pharma Inc. (OTCQB: SILO) to its growing cannabis and psychedelics client roster.
  • CFN Media will leverage its proprietary digital content platform and extensive distribution network-including its flagship CannabisFN and PsyIndex properties-to attract targeted retail, accredited and institutional investors to Silo Pharma Inc.
    "Silo Pharma has made tremendous promise in growing its presence in the psychedelics industry," said CFN Media President Frank Lane.
  • Silo Pharma is focused on the development of psychedelic therapeutics for neurological disorders including fibromyalgia, post-traumatic stress disorder and Parkinson's disease.
  • "We are excited to be working with CFN Media, one of the leading voices in the psychedelic investment community," said Silo Pharma Inc. Chairman and CEO Mr. Eric Weisblum.

This New Year, SMB Generic Drug Manufacturers Take Back Control with MDH Insight’s Trailblazing EmpowerRM® Pharma Chargeback Software

Wednesday, February 3, 2021 - 3:21pm

MDH Insights (MDH) game-changing in-house software EmpowerRM can be the best 2021 resolution embraced by small to mid-size generic pharma manufacturers that outsource their chargeback processing or do not have a revenue management system in place.

Key Points: 
  • MDH Insights (MDH) game-changing in-house software EmpowerRM can be the best 2021 resolution embraced by small to mid-size generic pharma manufacturers that outsource their chargeback processing or do not have a revenue management system in place.
  • According to MDH president and owner Matthew D. Hoenig, it is especially valuable for generic drug manufacturers financially squeezed by volumes of wholesaler chargebacks and experiencing related revenue leakage .
  • For emerging generic and brand drug manufacturers, EmpowerRMs software automates all contracts and chargeback processing to deliver a holistic revenue management solution that provides advanced validation, real-time visibility, detailed analytics and report generation.
  • It minimizes losses while increasing the profit margins of generic pharma manufacturers, all while giving them a competitive edge.

Eurofins Discovery Bolsters its Leadership for Integrated Drug Discovery

Wednesday, February 3, 2021 - 2:00pm

SAN DIEGO, Feb. 3, 2021 /PRNewswire/ -- Eurofins Discovery, the market leader in pharmacology services and drug discovery products with over forty years providing solutions for the pharmaceutical and biotech industry, announces Paul D. Ratcliffe, PhD, as its leader for its integrated drug discovery business unit, DiscoveryOne .

Key Points: 
  • SAN DIEGO, Feb. 3, 2021 /PRNewswire/ -- Eurofins Discovery, the market leader in pharmacology services and drug discovery products with over forty years providing solutions for the pharmaceutical and biotech industry, announces Paul D. Ratcliffe, PhD, as its leader for its integrated drug discovery business unit, DiscoveryOne .
  • Dr. Ratcliffe's experience in pharmaceutical drug discovery and development provides the knowledge and skill to drive DiscoveryOne Integrated Drug Discovery programs required by our clients in large pharma and biotech companies around the globe.
  • His broad knowledge from working on prominent drug targets in a variety of therapeutic areas and developing innovative approaches to drug discovery will provide our clients with unique skills as a trusted partner for their drug discovery programs.
  • With over 50,000 staff across a network of more than 800 laboratoriesin over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.

AMRI Wins 2021 CMO Leadership Awards

Monday, February 1, 2021 - 2:00pm

Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader.

Key Points: 
  • Albany Molecular Research, Inc. ( AMRI ), a leading global provider of advanced contract research, development and manufacturing solutions, today announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader.
  • Recognition in the CMO Leadership Awards reflects the scientific expertise and passion for patients demonstrated by AMRI teams across the world, said John Ratliff , CEO, AMRI.
  • AMRI received six CMO Leadership Awards across all performance categories: capabilities, compatibility, expertise, quality, reliability and service based on small pharma respondents in primary market research conducted by Industry Standard Research (ISR).
  • Congratulations to all the 2021 CMO Leadership Award winners; you keep the biopharma industry moving forward.